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Abstract
The relationship between elevated blood pressure and cardiovascular and cerebrovascular disease
risk is well accepted. Both systolic and diastolic hypertension are associated with this risk increase,
but systolic blood pressure appears to be a more important determinant of cardiovascular risk than
diastolic blood pressure. Subjects for this study are derived from the Framingham Heart Study data
set. Each subject had five records of clinical data of which systolic blood pressure, age, height,
gender, weight, and hypertension treatment were selected to characterize the phenotype in this
analysis.
We modeled systolic blood pressure as a function of age using a mixed modeling methodology that
enabled us to characterize the phenotype for each individual as the individual's deviation from the
population average rate of change in systolic blood pressure for each year of age while controlling
for gender, body mass index, and hypertension treatment. Significant (p = 0.00002) evidence for
linkage was found between this normalized phenotype and a region on chromosome 1. Similar
linkage results were obtained when we estimated the phenotype while excluding values obtained
during hypertension treatment. The use of linear mixed models to define phenotypes is a
methodology that allows for the adjustment of the main factor by covariates. Future work should
be done in the area of combining this phenotype estimation directly with the linkage analysis so that
the error in estimating the phenotype can be properly incorporated into the genetic analysis, which,
at present, assumes that the phenotype is measured (or estimated) without error.
Background
The relationship between elevated blood pressure and car-
diovascular and cerebrovascular disease risk is well
accepted. The lifetime risk estimate for developing hyper-
tension is 90% in patients who are 55 and 65 years old
[1]. Both systolic and diastolic hypertension are associ-
ated with this risk increase, but systolic blood pressure
appears to be a more important determinant of cardiovas-
cular risk than diastolic blood pressure [2]. It has also
been shown that systolic blood pressure alone is a signifi-
cant predictor of left ventricular mass in certain patients,
which in turn is a powerful independent predictor for car-
diovascular disease events [3]. Effective prevention of car-
diovascular disease requires maintaining normal blood
pressure levels throughout an individual's lifetime.
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In examining the effect of systolic blood pressure on car-
diovascular disease, it is beneficial to utilize subjects'
measurements taken over a period of time. This is because
multiple longitudinal blood pressure measurements or
long-term average blood pressure are more representative
of a person's average or true blood pressure than a single
measure for risk assessment [4]. Mixed model methodol-
ogy allows the longitudinal examination of systolic blood
pressure over time. In this manner we are able to assess
not only a person's long-term average, but also a person's
rate of change in systolic blood pressure over the study
period.
Evidence shows that one's genetic makeup is a strong
determinant of their risk of developing hypertension.
Families prone to higher systolic and diastolic blood pres-
sures also show higher rates of blood pressure increase
with age; however, few other studies have explored rate of
blood pressure increase [5]. The purpose of this study is to
search for genomic regions influencing the rate of change
in resting systolic blood pressure (SBP) in families consist-
ing of individuals enrolled in the Framingham Heart
Study.
Methods
Subjects
Subjects for this study are derived from Cohort 2 of the
Framingham Heart Study Data Set. Cohort 2 was selected
because it comprises offspring, thereby providing a higher
proportion of siblings than Cohort 1, which is the original
cohort with complex family structures. For details on
Cohort 2 subject selection, exclusion, distribution, and
methodology please refer to http://www.sfbr.org/gaw/
readme.Prob1.pdf. Of the 1671 subjects in Cohort 2,
1590 were included in the linear mixed model analysis, of
which the 1308 with genotype data were included in the
linkage analysis. Subjects were excluded from the linear
mixed model analysis if only one systolic blood pressure
measurement was done.
In the Cohort 2 data set, each subject has five records of
clinical data including but not limited to age, height,
weight, systolic blood pressure, cholesterol, fasting glu-
cose, and behavioral risk factors. The variables selected for
analysis in linear mixed models were systolic blood pres-
sure, age, height, weight, gender, and hypertension treat-
ment. The selection of these variables was based on past
studies investigating similar hypotheses [6,7] and because
these variables were the most complete.
Also considered was the impact of hypertension treatment
on the systolic blood pressure readings. Preliminary
graphs of individual systolic blood pressure data indicate
that subjects on medication have less linear data than sub-
jects not on medication. While subjects who received
treatment make up most of the individuals with high
blood pressure, we were concerned that measurements
from individuals on medication may be biased. Therefore,
we defined the phenotype in two ways: 1) we adjusted the
phenotype for hypertension treatment (as described
above) and 2) we set all blood pressure measures taken
while the individual was receiving treatment to missing.
We then conducted analyses on both phenotypes using
the same methods and presented the results separately for
comparison.
Linear mixed model analysis
The linkage analysis phenotype for each individual is the
best linear unbiased predictor of the individual's devia-
tion from the population rate of change in SBP for each
year of age while controlling for hypertension treatment,
sex, and BMI. The SBP for each individual was measured
every 4 years as part of the Framingham Heart Study. The
measurement data are not complete in every individual
and missing values exist. Given the longitudinal nature of
the data and the existence of missing data, linear mixed
models were utilized for the slope generation. Linear
mixed models also allow for selected covariates to be
adjusted for in the analysis such as whether the subject
was taking hypertension medication. The model form is
described below.
Yi = Xiβ + WiΓ + Zibi + εI  ,
where
Yi: the vector of systolic blood pressures for individual i
β: vector containing the intercept and slope of the regres-
sion of systolic blood pressure on age
Xi: design matrix associated with β
Γ: vector containing regression coefficients on covariates
gender, BMI, and hypertension treatment
Wi: design matrix associated with covariates gender, BMI,
and hypertension treatment
bi: vector of random effects due to age and BMI
Zi: design matrix associated with random effects due to
age and BMI
εI: random error vector for each individual.
Assumptions for the random elements are:
The εi ~ i.i.d. N(0, Σi).BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/s1/S83
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The bi ~ i.i.d. N(0, D).
The ε and bi are independent.
Using SAS, we modeled SBP as a function of age using
mixed modeling methodology that enabled us to estimate
the population average curve as well as the subject-specific
curves based on best linear unbiased predictors. The
regression model for each individual was adjusted for gen-
der, BMI, and hypertension treatment. The best linear
unbiased estimator of the random effect of the regression
coefficient on age, b1, was the phenotype in our genetic
analysis. The phenotype for each individual was inter-
preted as the individual's deviation from the population
average rate of change in SBP for each year of age while
controlling for gender, BMI, and hypertension treatment.
Lastly, the phenotype was converted into a Z-score value
for use in the S.A.G.E. 4.2 program [8].
A secondary analysis excluding hypertension treatment
was conducted to compare with results acquired when
adjusting for treatment. To do this analysis, if a SBP meas-
urement was taken while the subject was taking hyperten-
sion medication, the SBP measurement was converted to
a missing value. Mixed models were then used with the
new SBP measurements to get the new phenotype of indi-
vidual's deviation from the population average rate of
change in SBP for each year of age while controlling for
gender and BMI. This phenotype was also converted to a
Z-score value for use in the S.A.G.E. 4.2 program [8].
Genetic linkage analysis
Linkage analysis using sibling pairs can be defined by the
regression of the squared sib-pair trait difference on the
estimated proportion of alleles siblings share identical by
descent [8]. The SIBPAL4.2 function in SAGE4.2 software
was utilized for the linkage analysis. SIBPAL4.2 is based
on the hypothesis that if a given marker is cosegregating
with a disease allele, then siblings who are more pheno-
typically similar are more likely to have received the same
allele identical by decent (IBD) at a closely linked marker
locus than if the marker locus was segregating independ-
ently of the disease allele.
Initially, the pedigree data set was run through the Identi-
cal by Descent4.2 (IBD) procedure of SAGE using the sin-
gle-point option. The resulting IBD file along with a
pedigree file and a parameter file were utilized in the non-
parametric linkage analysis of SIBPAL4.2 to identify
genetic linkage on the basis of sib-pair phenotypes as
defined by the mixed model results. Only full sibs were
used in this sibship analysis.
Results
Descriptive statistics of normalized phenotype values are
shown in Table 1. There were no marker inconsistencies
identified in the data set, however, if inconsistencies had
been identified, SIBPAL4.2 analysis would have removed
them from the analysis.
Significance of the linkage results was evaluated using the
criteria of Lander and Kruglyak [9]. With adjustment of
the phenotype for hypertension treatment, two contigu-
ous markers on chromosome 1 showed significant (p =
0.00002) evidence for linkage to SBP rate of change, as
indicated by the bold text in Table 2. Eight additional
markers on chromosomes 1, 2, 3, 5, 8, and 17 showed
weak evidence for linkage to the phenotype with adjust-
ment for hypertension treatment.
When SBP values taken during hypertension treatment are
excluded, the same region on chromosome 1 shows sig-
nificant or suggestive evidence for linkage to SBP rate of
change, as indicated by the bold text in Table 3. Five addi-
tional markers on chromosomes 1, 3, 8, and 17 showed
weak evidence for linkage to the SBP rate of change phe-
notype after exclusion of hypertension treated SBP values.
Discussion
In this study, a linear mixed modeling methodology was
used to identify SBP phenotypes for each subject. The use
Table 1: Description of each normalized phenotype of SBP rate of change
Adjusting for Hypertension Treatment Excluding SBP Values Taken During 
Hypertension Treatment
N 1590 1496
Mean 0.079 0.061
Median -0.117 -0.135
Std Deviation 1.177 1.200
Minimum -4.44 -4.70
Maximum 6.33 6.39BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/s1/S83
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of mixed models was appropriate here given the longitu-
dinal nature of the data. By using linear mixed models
with best linear unbiased predictors, the phenotype of rate
of change can be defined as the slope for each subject
while adjusting the values for other covariates. Studies
have examined various methodologies for using longitu-
dinal data to identify individual phenotypes [7,10] and to
control for covariates. While slightly different linkage
results were obtained in these studies, it is difficult to
determine whether these discrepancies were due to the use
of different methodologies for defining the phenotype or
other reasons.
For example, Levy et al. [10] defined the phenotype by a
two-stage process of calculating within-subject mean SBP
and then using regression analysis to adjust for BMI and
age to yield a residual for each individual. A nonparamet-
ric algorithm was used to adjust the residuals for hyper-
tension medication. Levy et al. found linkage to regions
on chromosomes 5, 9, 10, and 17. The Levy phenotype
definition methodology is different from the definition
presented here, in that they used the individual regression
residual derived from sample-wide regressions that
adjusted for age and BMI. However, regression residuals
have some similarities to our methods in that they repre-
sent the difference between the population rate of change
and observed values. Therefore, the fact that Levy et al.
and we found linkage of our hypertension phenotypes to
the same region on chromosome 5 is not surprising. The
replication of these two studies, using differing methodol-
ogies in the definition of the phenotype, suggest that the
region on chromosome 5 may contain a gene for average
SBP over time, or rate of change of SBP, or both. Past stud-
ies have also found evidence for linkage on at least one of
the chromosomes identified in this and Levy et al.'s study
[11-15].
We found significant evidence for linkage of SBP rate of
change to a region on chromosome 1 (~188–269 cM).
Interestingly, we found similar linkage results regardless
of whether we excluded values under hypertension treat-
ment or adjusted for hypertension treatment in our
definition of the phenotype. A region with at least two sta-
tistically significant markers, such as that found on
chromosome 1, may indicate a region in which a candi-
date gene associated with the rate of change in SBP may
Table 2: Linkage results using the normalized phenotype of SBP rate of change with adjustment for hypertension treatment
Chromosome Marker Distance (kb) Estimate Std Error p-Value
c1g21 GGAA22G10 211.97 0.2957 0.1240 0.00864
c1g22A ATA4E02 223.13 0.4280 0.1132 0.000082
c1g23 GATA7C01 234.37 0.4563 0.1206 0.000081
c1g29 ATA29C07 271.59 0.3631 0.1258 0.0020
c2g3 GGAA20G10 30.43 0.3145 0.1315 0.0085
c3g19 GATA148E04 167.93 0.2731 0.1161 0.0094
c5g11 GATA21D04 63.39 0.3094 0.1235 0.0062
c8g4 GATA23D06 28.6 0.3456 0.1138 0.0012
c8g17 GATA21C12 151.8 0.3467 0.1197 0.0019
c17g14 GATA73F01 108.27 0.3461 0.1316 0.0043
*Bold text indicates significant evidence for linkage.
Table 3: Linkage results using the normalized phenotype of systolic blood pressure rate of change when excluding values taken during 
hypertension treatment
Chromosome Marker Distance (kb) Estimate Std Error p-value
c1g21 GGAA22G10 211.97 0.3547 0.1468 0.00793
c1g22A ATA4E02 223.13 0.5090 0.1389 0.000129
c1g23 GATA7C01 234.37 0.6635 0.1471 0.000003
c3g19 GATA148E04 167.93 0.3338 0.1411 0.0091
c8g4 GATA23D06 28.6 0.3384 0.1404 0.0080
c8g5 GATA72C10 40.52 0.4183 0.1589 0.0042
c17g14 GATA73F01 108.27 0.4142 0.1608 0.0051
ABold text indicates significant or suggestive evidence for linkage.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/s1/S83
Page 5 of 5
(page number not for citation purposes)
lie. This region has not been as heavily studied as those
mentioned previously, but is a viable candidate region
because of the proximity of the angiotensinogen gene
(~244–251 cM) [16]. Two previous linkage studies of a
hypertension phenotype have found peak lod scores at
192 cM in this region on chromosome 1 [17,18]. These
findings focus interest on this region of chromosome 1 for
further research into localizing and identifying one or
more candidate gene(s), which may or may not include
angiotensinogen.
The use of linear mixed models to define phenotypes is a
methodology that allows for the adjustment of the main
factor by covariates. The phenotypes defined for each sub-
ject are continuous and generalizable. Future work should
be done in the area of combining this phenotype estima-
tion directly with the linkage analysis so that the error in
estimating the phenotype can be properly incorporated
into the genetic analysis, which, at present, assumes that
the phenotype is measured (or estimated) without error.
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